[1. World Health Organization. Guidelines for the diagnosis, treatment, and prevention of leprosy. New Delhi: World Health Organization; 2018.]Search in Google Scholar
[2. Pandhi D, Chhabra N. New insights in the pathogenesis of type 1 and type 2 lepra reaction. Indian J Dermatol Venereol Leprol. 2013;79(6):739-49.10.4103/0378-6323.120719]Search in Google Scholar
[3. Nery JA da C, Bernardes Filho F, Quintanilha J, Machado AM, Oliveira S de S, Sales AM. Understanding the type 1 reactional state for early diagnosis and treatment: a way to avoid disability in leprosy. An Bras Dermatol. 2013;88(5):787-92.10.1590/abd1806-4841.20132004]Search in Google Scholar
[4. Scollard DM, Smith T, Bhoopat L, Theetranont C, Rangdaeng S, Morens DM. Epidemiologic characteristics of leprosy reactions [Internet]. Int J Lepr Other Mycobact Dis. 1994 [cited 2018 Dec 11];62(4):559-67. Available from: http://ila.ilsl.br/pdfs/v62n4a09.pdf]Search in Google Scholar
[5. Kumar B, Dogra S, Kaur I. Epidemiological characteristics of leprosy reactions: 15 years experience from north India. Int J Lepr Other Mycobact Dis. 2004;72(2):125-33.10.1489/1544-581X(2004)072<0125:ECOLRY>2.0.CO;2]Search in Google Scholar
[6. Lockwood DN, Vinayakumar S, Stanley JN, Mcadam KP, Colston MJ. Clinical features and outcome of reversal (type 1) reactions in Hyderabad, India. Int J Lepr Other Mycobact Dis. 1993;61(1):8-15.]Search in Google Scholar
[7. Roche PW, Le Master J, Butlin CR. Risk factors for type 1 reactions in leprosy [Internet]. Int J Lepr Other Mycobact Dis. 1997 [cited 2018 Dec 12];65(4):450-5. Available from: http://ila.ilsl.br/pdfs/v65n4a02.pdf.]Search in Google Scholar
[8. Motta AC, Pereira KJ, Tarquínio DC, Vieira MB, Miyake K, Foss NT. Leprosy reactions: coinfections as a possible risk factor. Clinics (Sao Paulo). 2012;67(10):1145-8.10.6061/clinics/2012(10)05]Search in Google Scholar
[9. Nery JA da C, Duppre NC, Sales AM, Machado AM, Jardim RM, Illarramendi X. Contribution to diagnosis and management of reactional states: a practical approach. An Bras Dermatol. 2006;81(4):367-75.]Search in Google Scholar
[10. Kamath S, Vaccaro SA, Rea TH, Ochoa MT. Recognizing and managing the immunologic reactions in leprosy. J Am Acad Dermatol. 2014;71(4):795-803.10.1016/j.jaad.2014.03.034]Search in Google Scholar
[11. White C, Franco-Paredes C. Leprosy in the 21st century. Clin Microbiol Rev. 2015;28(1):80-94.10.1128/CMR.00079-13]Search in Google Scholar
[12. Naafs B. Clinical aspects of the reversal reaction. Hansenol Int. 1998;(Special):72-8.]Search in Google Scholar
[13. Khadge S, Banu S, Bobosha K, van der Ploeg-van Schip JJ, Goulart IM, Thapa P, et al. Longitudinal immune profiles in type 1 leprosy reactions in Bangladesh, Brazil, Ethiopia and Nepal. BMC Infect Dis. 2015;15:477.10.1186/s12879-015-1128-0]Search in Google Scholar
[14. Geluk A, van Meijgaarden KE, Wilson L, Bobosha K, van der Ploeg-van Schip JJ, van den Eeden SJ, et al. Longitudinal immune responses and gene expression profiles in type 1 leprosy reactions. J Clin Immunol. 2014;34(2):245-55.10.1007/s10875-013-9979-x]Search in Google Scholar
[15. Andersson AK, Chaduvula M, Atkinson SE, Khanolkar-Young S, Jain S, Suneetha L, et al. Effects of prednisolone treatment on cytokine expression in patients with leprosy type 1 reactions. Infect Immun. 2005; 73(6):3725-33.10.1128/IAI.73.6.3725-3733.2005]Search in Google Scholar
[16. Naafs B. Bangkok Workshop on Leprosy Research. Treatment of reactions and nerve damage. Int J Lepr Other Mycobact Dis. 1996;64(4 Suppl):S21-8.]Search in Google Scholar
[17. Wagenaar IM. Risk factors, early detection and treatment of neuropathy in leprosy. Rotterdam: Erasmus University Rotterdam; 2016.]Search in Google Scholar
[18. Oliveira MB, Diniz LM. Leprosy among children under 15 years of age: literature review. An Bras Dermatol. 2016;91(2):196-203.10.1590/abd1806-4841.20163661]Search in Google Scholar
[19. Rose P, Waters MF. Reversal reactions in leprosy and their management. Lepr Rev. 1991;62(2):113-21.10.5935/0305-7518.199100131870373]Search in Google Scholar
[20. Selvasekar A, Geetha J, Nisha K, Manimozhi N, Jesudasan K, Rao PS. Childhood leprosy in an endemic area. Lepr Rev. 1999;70(1):21-7.10.5935/0305-7518.1999000610405540]Search in Google Scholar
[21. Walker SL, Lockwood DNJ. Leprosy type 1 (reversal) reactions and their management. Lepr Rev. 2008;79 (4):372-86.10.47276/lr.79.4.372]Search in Google Scholar
[22. Raju R, Suneetha S, Jadhav RS, Chaduvula M, Atkinson S, Jain S, et al. Serological responses to prednisolone treatment in leprosy reactions: study of TNF-α, antibodies to and S100-B. Lipids Health Dis. 2014;13:119.10.1186/1476-511X-13-119412450725070345]Search in Google Scholar
[23. Chhabra N, Bhattacharya SN, Singal A, Ahmed RS, Verma P. Profile of oxidative stress in response to treatment for type 1 leprosy reaction. Lepr Rev. 2015;86(1):80-8.10.47276/lr.86.1.80]Search in Google Scholar
[24. Morato-Conceicao YT, Alves-Junior ER, Arruda TA, Lopes JC, Fontes CJ. Serum uric acid levels during leprosy reaction episodes. PeerJ. 2016;4:e1799.10.7717/peerj.1799479333026989632]Search in Google Scholar
[25. Wagenaar I, Post E, Brandsma W, Bowers B, Alam K, Shetty V, et al. Effectiveness of 32 versus 20 weeks of prednisolone in leprosy patients with recent nerve function impairment: a randomized controlled trial. PLoS Negl Trop Dis. 2017;11(10):e0005952.10.1371/journal.pntd.0005952564313328976976]Search in Google Scholar
[26. Lambert SM, Alembo DT, Nigusse SD, Yamuah LK, Walker SL, Lockwood DN. A randomized controlled double blind trial of ciclosporin versus prednisolone in the management of leprosy patients with new type 1 reaction, in Ethiopia. PLoS Negl Trop Dis. 2016;10(4):e0004502.10.1371/journal.pntd.0004502482153527046330]Search in Google Scholar
[27. Gabriel MTG, Hipolito RH, Chan GP, Senador LR, Lagda D, Gajete FC. Safety and efficacy of oral fusidic acid as a steroid-sparing agent in the treatment of lepra reactions : a randomized controlled assessor-blinded clinical trial. Journal of the Philippine Dermatological Society. 2015;24(2):20-9.]Search in Google Scholar
[28. Durães SM, Salles Sde A, Leite VR, Gazzeta MO. Azathioprine as a steroid sparing agent in leprosy type 2 reactions: report of nine cases. Lepr Rev. 2011;82(3):304-9.10.47276/lr.82.3.304]Search in Google Scholar
[29. Sahay G, Kar HK, Gupta R. Effect of steroid prophylaxis on nerve function impairment in multi-bacillary leprosy patients on MDT-MB. Indian J Lepr. 2015;87(3):133-43.]Search in Google Scholar
[30. Smith WC, Anderson AM, Withington SG, van Brakel WH, Croft RP, Nicholls PG, et al. Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomised placebo controlled trial (TRIPOD 1). BMJ. 2004;328(7454):1459.10.1136/bmj.38107.645926.AE42851115159285]Search in Google Scholar